A New FDA Approval in Triple-Negative Breast Cancer: Datopotamab Deruxtecan (Datroway) Gets the Green Light!
The U.S. Food and Drug Administration (FDA) has approved a next-generation antibody-drug conjugate in the fight against aggressive triple-negative breast cancer. This development opens the door to an important treatment option for metastatic patients who are not eligible for immunotherapy.
May 22, 2026 — As of May 22, 2026, the FDA officially approved datopotamab deruxtecan-dlnk (Datroway), developed by Daiichi Sankyo. The approval covers adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not eligible for PD-1/PD-L1 inhibitor therapy.
Triple-negative breast cancer is one of the most aggressive subtypes of breast cancer; because it lacks hormone receptors and HER2 expression, it does not respond to conventional targeted therapies. This approval marks a meaningful therapeutic advance for this patient group.
The Study Behind the Approval: TROPION-Breast02
The approval is based on data from the multicenter, randomized TROPION-Breast02 clinical trial, which enrolled a total of 644 patients. The Datroway arm was compared with the standard chemotherapy arm and demonstrated significant superiority across all three key efficacy endpoints:
- Progression-Free Survival (PFS): Median PFS in the Datroway arm was recorded at 10.8 months, compared with 5.6 months in the standard chemotherapy arm.
- Overall Survival (OS): Median overall survival increased from 18.7 months to 23.7 months versus the chemotherapy arm.
- Overall Response Rate (ORR): The response rate rose from the 30% offered by chemotherapy to 64%.
💬 Why Does It Matter?
Triple-negative breast cancer is known for its limited treatment options and rapidly progressing course. Options narrow even further for patients who are not eligible for immunotherapy (PD-1/PD-L1 inhibitors). By nearly doubling progression-free survival and raising the response rate from 30% to 64%, Datroway represents a remarkable advance for this challenging patient population.
Important Warnings and Safety Profile
The Datroway prescribing information includes important warnings and precautions regarding certain risks that require close monitoring:
- Interstitial Lung Disease / Pneumonitis: The risk of potentially serious lung inflammation must be monitored closely.
- Ocular (Eye) Reactions: Various eye-related adverse effects may occur.
- Stomatitis / Oral Mucositis: Inflammation and sores may develop in the mouth.
- Embryo-Fetal Toxicity: Due to the risk of harm to the fetus during pregnancy, the necessary precautions must be taken.
Conclusion
This FDA approval has gone down as a highly important therapeutic advance for patients with metastatic triple-negative breast cancer, an aggressive form of cancer. Demonstrating the continued rise of antibody-drug conjugate (ADC) technology in breast cancer treatment, the approval opens a new and effective door for patients who are not eligible for immunotherapy.